{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:05:45Z","timestamp":1780095945773,"version":"3.54.0"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,5,15]]},"DOI":"10.2169\/internalmedicine.0506-22","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T22:19:08Z","timestamp":1664921948000},"page":"1389-1394","source":"Crossref","is-referenced-by-count":6,"title":["Degree of Gastric Mucosal Atrophy Correlated Well with Gastric Cancer Occurrence in Patients with &lt;i&gt;Helicobacter pylori&lt;\/i&gt;-eradicated Status"],"prefix":"10.2169","volume":"62","author":[{"given":"Kyoichi","family":"Adachi","sequence":"first","affiliation":[{"name":"Health Center, Shimane Environment and Health Public Corporation, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Kishi","sequence":"additional","affiliation":[{"name":"Health Center, Shimane Environment and Health Public Corporation, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utae","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Health Center, Shimane Environment and Health Public Corporation, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Infection with <i>Helicobacter pylori<\/i>. IARC Monogr Eval Carcinog Risks Hum 61: 177-240, 1994."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Uemura N, Okamoto S, Yamamoto S, et al. <i>Helicobacter pylori<\/i> infection and the development of gastric cancer. N Engl J Med 345: 784-789, 2001.","DOI":"10.1056\/NEJMoa001999"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with <i>Helicobacter pylori<\/i> infection increases risk of gastric cancer. Int J Cancer 109: 138-143, 2004.","DOI":"10.1002\/ijc.11680"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of <i>Helicobacter pylori<\/i> on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392-397, 2008.","DOI":"10.1016\/S0140-6736(08)61159-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Choi IJ, Kook MC, Kim YI, et al. <i>Helicobacter pylori<\/i> therapy for the prevention of metachronous gastric cancer. N Engl J Med 378: 1085-1095, 2018.","DOI":"10.1056\/NEJMoa1708423"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Lee YC, Chiang TH, Chou CK, et al. Association between <i>Helicobacter pylori<\/i> eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 150: 1113-1124.e5, 2016.","DOI":"10.1053\/j.gastro.2016.01.028"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with <i>Helicobacter pylori<\/i> eradication and consecutive surveillance in Japan. J Gastroenterol 49: 1-8, 2014.","DOI":"10.1007\/s00535-013-0897-8"},{"key":"8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gutjnl-2014-307094","volume":"64","author":"K Asada","year":"2015","unstructured":"8. Asada K, Nakajima T, Shimazu T, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 64: 388-396, 2015.","journal-title":"Gut","ISSN":"https:\/\/id.crossref.org\/issn\/0017-5749","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shichijo S, Hirata Y. Characteristics and predictors of gastric cancer after <i>Helicobacter pylori<\/i> eradication. World J Gastroenterol 24: 2163-2172, 2018.","DOI":"10.3748\/wjg.v24.i20.2163"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shichijo S, Uedo N, Michida T. Detection of early gastric cancer after <i>Helicobacter pylori<\/i> eradication. Digestion 103: 54-61, 2022.","DOI":"10.1159\/000519838"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Notsu T, Adachi K, Mishiro T, Ishimura N, Ishihara S. Fundic gland polyp prevalence according to <i>Helicobacter pylori<\/i> infection status. J Gastroenterol Hepatol 35: 1158-1162, 2020.","DOI":"10.1111\/jgh.14934"},{"key":"12","unstructured":"12. Kyoto Classification of Gastritis. Haruma K, Ed. Nihon Medical Center, Tokyo, 2017."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Watanabe K, Nagata N, Nakashima R, et al. Predictive findings for <i>Helicobacter pylori<\/i>-uninfected, -infected and -eradicated gastric mucosa: validation study. World J Gastroenterol 19: 4374-4379, 2013.","DOI":"10.3748\/wjg.v19.i27.4374"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kato M, Terao S, Adachi K, et al.; Study Group for Establishing Endoscopic Diagnosisi of Chronic Gastritis. Changes in endoscopic findings of gastritis after cure of <i>H. pylori<\/i> infection: multicenter prospective trial. Dig Endosc 25: 264-273, 2013.","DOI":"10.1111\/j.1443-1661.2012.01385.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Adachi K, Notsu T, Mishiro T, Kinoshita Y. Relationship of <i>Helicobacter pylori<\/i> infection with gastric black spots shown by endoscopy. Intern Med 58: 767-772, 2019.","DOI":"10.2169\/internalmedicine.1751-18"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Adachi K, Mishiro T, Okada M, Kinoshita Y. Prevalence of multiple white and flat elevated lesions in individuals undergoing a medical checkup. Intern Med 57: 1213-1218, 2018.","DOI":"10.2169\/internalmedicine.9808-17"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1: 87-97, 1969.","DOI":"10.1055\/s-0028-1098086"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.","DOI":"10.1111\/apm.1965.64.1.31"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNA methylation in <i>Helicobacter pylori<\/i>-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12: 989-995, 2006.","DOI":"10.1158\/1078-0432.CCR-05-2096"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Chan AO, Peng JZ, Lam SK, et al. Eradication of <i>Helicobacter pylori<\/i> infection reverses E-cadherin promoter hypermethylation. Gut 55: 463-468, 2006.","DOI":"10.1136\/gut.2005.077776"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Perri F, Cotugno R, Piepoli A, et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. pylori infected patients and effect of eradication. Am J Gastroenterol 102: 1361-1371, 2007.","DOI":"10.1111\/j.1572-0241.2007.01284.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nakajima T, Enomoto S, Yamashita S, et al. Persistence of a component of DNA methylation in gastric mucosae after <i>Helicobacter pylori<\/i> eradication. J Gastroenterol 45: 37-44, 2010.","DOI":"10.1007\/s00535-009-0142-7"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/10\/62_0506-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T03:25:47Z","timestamp":1684553147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/10\/62_0506-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0506-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"article-number":"0506-22"}}